{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:12:23Z","timestamp":1787314343746,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This randomized, double\u2010blind, single\u2010 and multiple\u2010ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu\u2122), a selective and potent small\u2010molecule inhibitor of tyrosine kinase 2, in 100 (75 active, 25 placebo) healthy volunteers (NCT02534636). Deucravacitinib was rapidly absorbed, with a half\u2010life of 8\u201315\u2009h, and 1.4\u20131.9\u2010fold accumulation after multiple dosing. Deucravacitinib inhibited interleukin (IL)\u201012\/IL\u201018\u2010induced interferon (IFN)\u03b3 production ex vivo in a dose\u2010 and concentration\u2010dependent manner. Following in vivo challenge with IFN\u03b1\u20102a, deucravacitinib demonstrated dose\u2010dependent inhibition of lymphocyte count decreases and expression of 53 IFN\u2010regulated genes. There were no serious adverse events (AEs); the overall frequency of AEs was similar in the deucravacitinib (64%) and placebo (68%) groups. In this first\u2010in\u2010human study, deucravacitinib inhibited IL\u201012\/IL\u201023 and type I IFN pathways in healthy volunteers, with favorable PK and safety profiles. Deucravacitinib is a promising therapeutic option for immune\u2010mediated diseases, including Crohn's disease, psoriasis, psoriatic arthritis, and systemic lupus erythematosus.<\/jats:p>","DOI":"10.1111\/cts.13435","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T05:11:32Z","timestamp":1667452292000},"page":"151-164","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["<scp>First\u2010in\u2010human<\/scp>\n                    study of deucravacitinib: A selective, potent, allosteric\n                    <scp>small\u2010molecule<\/scp>\n                    inhibitor of tyrosine kinase 2"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-2626","authenticated-orcid":false,"given":"Ian M.","family":"Catlett","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi","family":"Aras","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hansen","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liu","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Bei","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab G.","family":"Girgis","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Murthy","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Bristol Myers Squibb.SOTYKTU (deucravacitinib) prescribing information;2022. Accessed May 10 2022.https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00211.x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.619502"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1930781100"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.672048"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1974"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10419.x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32167-6"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo\u2010controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"Vollenhoven RF","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00291-5"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20131174"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1964-1"},{"key":"e_1_2_11_19_1","first-page":"1","article-title":"BMS\u2010986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks IL\u201012, IL\u201023 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease","volume":"68","author":"Gillooly K","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12517"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.001"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00443"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120231"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90003-X"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.198"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E14-12-1645"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.2211"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew427"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34632"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37824"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.5020a"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13435","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13435","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T12:06:42Z","timestamp":1692446802000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/cts.13435"],"URL":"https:\/\/doi.org\/10.1111\/cts.13435","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"2022-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}